{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} ACCC Report Shows Major Growth in Immuno-Oncology Despite Pandemic

Activity Steps

1 Activity
2 Take Test 3Certificate

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Describe new IO treatment options, determined by the ACCC's Immuno-Oncology Institute's survey.
  2. Summarize insights from the ACCC report regarding future directions in IO.

Learning Outcomes

To present an overview of an annual immuno-oncology (IO) report from the Association of Community Cancer Centers (ACCC), "Immuno-Oncology in 2021: Committed to the Cutting Edge of Care."

Disclosures

The author(s), faculty, staff, and planners in any position to control the content of this activity, have disclosed that they have no financial relationships with, or financial interests in, any commercial companies relevant to this educational activity.

Price: $12.95

Credits:

  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.







Planner
Test Code: OT0921
Published: September 2021
Expires: 9/6/2024
Sources: Oncology Times
Required Passing Score: 8/10 (80%)
Authors: Peggy Eastman
Categories: Advanced Practice Nursing , Cancer , Oncology
Specialties: Advanced Practice Nursing, Oncology
Topics: COVID-19 , Immunotherapy